Afelimomab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAfelimomab

Drug Alias Name阿非莫单抗Anti-tumour necrosis factor Fab antibody阿非利莫单抗SegardMAK-195F

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine

Mechanisms of ActionTumor necrosis factor inhibitors

TargetsTumor necrosis factor

Therapy Area/IndicationsGraft vs Host DiseaseShock, SepticSepsis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbott Laboratories

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsGraft vs Host DiseaseShock, SepticSepsis

ATC CodeL04AB03